NCT03691311 - Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

July 5, 2022

Study Completion Date

February 5, 2023

Conditions

Breast Neoplasm FemaleStage I Breast CancerStage II Breast CancerHormone Receptor Negative NeoplasmHormone Receptor Positive Tumor

Interventions

DRUG

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Two injections on days 1 and 8 previous to surgery breast cancer excision

Trial Locations (1)

Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat